Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Nabi’s StaphVAX Development Back On Track

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

The company is seeking a partner for the re-launch of its gram-positive bacteria vaccine program.

You may also be interested in...



Nabi Sells Biologics Business To German Plasma Protein Firm Biotest

Nabi met with FDA Sept. 11 concerning components and a timeline for completion of its Nabi-HB IV BLA, pending at the agency since 2002.

Nabi Sells Biologics Business To German Plasma Protein Firm Biotest

Nabi met with FDA Sept. 11 concerning components and a timeline for completion of its Nabi-HB IV BLA, pending at the agency since 2002.

Nabi Drops StaphVAX Following Failure Of Confirmatory Trial

Firm also halts development of S. aureus immune globulin Altastaph because it uses the same technology as the StaphVax S. aureus vaccine.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’

Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116

Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length

German HTA Queries Polivy Benefits Amid Lack Of Evidence

See All
UsernamePublicRestriction

Register

PS063892

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By